• 1
    Dalton WS, Jove R. Drug resistance in multiple myeloma: approaches to circumvention. Semin Oncol. 1999; 26: 2327.
  • 2
    Dalton WS. Mechanisms of drug resistance in hematologic malignancies. Semin Hematol. 1997; 34: 38.
  • 3
    Sonneveld P, Lokhorst HM, Vossebeld P. Drug resistance in multiple myeloma. Semin Hematol. 1997; 34: 3439.
  • 4
    Gregory WM, Richards MA, Malpas JS. Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials. J Clin Oncol. 1992; 10: 334342.
  • 5
    Salmon SE, Cassady JR. Plasma cell neoplasms. In: DeVitaVTJr., HellmanS, RosenbergSA. Cancer: principles and practice of oncology, 5th ed. Philadelphia: Lippincott-Raven, 1997: 23442387.
  • 6
    Alexanian R, Dimopoulos M. Drug therapy: the treatment of multiple myeloma. N Engl J Med. 1994; 330: 484489.
  • 7
    Lokhorst HM, Meuwissen OJ, Bast EJ, Dekker AW. VAD chemotherapy for refractory multiple myeloma. Br J Haematol. 1989; 71: 2530.
  • 8
    Alexanian R, Barlogie B, Tucker S. VAD-based regimens as primary treatment for multiple myeloma. Am J Hematol. 1990; 33: 8689.
  • 9
    Barlogie B, Smith L, Alexanian R. Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med. 1984; 310: 13531356.
  • 10
    Samson D, Gaminara E, Newland A, et al. Infusion of vincristine and doxorubicin with oral dexamethasone as first-line therapy for multiple myeloma. Lancet. 1989; 2: 882885.
  • 11
    Lefrak EA, Pitha J, Rosenheim S, Gottlieb JA. A clinicopathologic analysis of Adriamycin cardiotoxicity. Cancer. 1973; 32: 302314.
  • 12
    Steinherz LJ, Steinherz PG, Tan CT, Heller G, Murphy ML. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA. 1991; 266: 16721677.
  • 13
    Von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979; 91: 710717.
  • 14
    Martin FJ. Pegylated liposomal doxorubicin: scientific rationale and preclinical pharmacology. Oncology. 1997; 11: 1120.
  • 15
    Papahadjopoulos D, Allen TM, Gabizon A, et al. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci USA. 1991; 88: 1146011464.
  • 16
    Papahadjopoulos D, Gabizon A. Liposomes designed to avoid the reticuloendothelial system. Prog Clin Biol Res. 1990; 343: 8593.
  • 17
    Gabizon A, Martin F. Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours. Drugs. 1997; 54: 1521.
  • 18
    Gabizon A, Catane R, Uziely B, et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res. 1994; 54: 987992.
  • 19
    Rahman A, Treat J, Roh JK, et al. A phase I clinical trial and pharmacokinetic evaluation of liposome-encapsulated doxorubicin. J Clin Oncol. 1990; 8: 10931100.
  • 20
    Northfelt DW, Martin FJ, Working P, et al. Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma. J Clin Pharmacol. 1996; 36: 5563.
  • 21
    Speth PAJ, van Hoesel QGCM, Haanen C. Clinical pharmacokinetics of doxorubicin. Clin Pharmacokinet. 1988; 15: 1531.
  • 22
    Huang SK, Mayhew E, Gilani S, Lasic DD, Martin FJ, Papahadjopoulos D. Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma. Cancer Res. 1992; 52: 67746781.
  • 23
    Berry G, Billingham M, Alderman E, et al. The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin. Ann Oncol. 1998; 9: 711716.
  • 24
    Rajkumar SV, Leong T, Roche PC, et al. Prognostic value of bone marrow angiogenesis in multiple myeloma. Clin Cancer Res. 2000; 6: 31113116.
  • 25
    Ribatti D, Vacca A, Nico B, et al. Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma. Br J Cancer. 1999; 79: 451455.
  • 26
    Vacca A, Ribatti D, Roncali L, et al. Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol. 1994; 87: 503508.
  • 27
    Barlogie B, Drewinko B, Benjamin RS, Freireich EJ. Kinetic response of human lymphoid cells to Adriamycin-DNA complex in vitro. Cancer Res. 1976; 36: 25402544.
  • 28
    Chen YH, Feng XX, Schilder L. Effect of vincristine, Adriamycin and glucocorticoids on myeloma cells in vitro. Acta Haematol. 1993; 89: 6169.
  • 29
    Gautier M, Petros W, Peterson B, Hurwitz H. Doxil, vincristine and dexamethasone: a new regimen for elderly patients with multiple myeloma [Abstract]. Proc Am Soc Clin Oncol. 1999; 18: 28a.
  • 30
    Tsiara SN, Kapsali E, Christou L, Panteli A, Pritsivelis N, Bourantas KL. Administration of a modified chemotherapeutic regimen containing vincristine, liposomal doxorubicin and dexamethasone to multiple myeloma patients: preliminary data. Eur J Haematol. 2000; 65: 118122.
  • 31
    Browman GP, Belch A, Skillings J, et al. Modified Adriamycin-vincristine-dexamethasone (m-VAD) in primary refractory and relapsed plasma cell myeloma: an NCI (Canada) pilot study. The National Cancer Institute of Canada Clinical Trials Group. Br J Haematol. 1992; 82: 555559.
  • 32
    Beckmann MJ, Hussein MA, Litchtin A, Jacobsen DW, Manteuffel L, Green R. Low serum vitamin B12 in patients with plasma cell myeloma is associated with true functional cobalamin deficiency [Abstract]. Am J Clin Pathol. 1995; 104: 350.
  • 33
    Nagore E, Insa A, Sanmartin O. Antineoplastic therapy-induced palmar plantar erythrodysesthesia (‘hand-foot’) syndrome. Incidence, recognition and management. Am J Clin Dermatol. 2000; 1: 225234.
  • 34
    Data on File. A multi-center randomized study of vincristine, Doxil®, and dexamethasone versus vincristine, doxorubicin, and dexamethasone in patients with multiple myeloma. Clinical protocol C-2000-003-00. Mountain View, Calif: Alza Corporation; August 22, 2000.
  • 35
    Alexanian R, Balcerzak S, Bonnet JD, et al. Prognostic factors in multiple myeloma. Cancer. 1975; 36: 11921201.
  • 36
    Browman GP, Bergsagel D, Sicheri D, et al. Randomized trial of interferon maintenance in multiple myeloma: a study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1995; 13: 23542360.
  • 37
    Sezer O, Niemoller K, Eucker J, et al. Bone marrow microvessel density is a prognostic factor for survival in patients with multiple myeloma. Ann Hematol. 2000; 79: 574577.
  • 38
    Hussein MA, Elson P, Hsi E, Srkalovic G. Doxil (D), vincristine (V), and decadron (d) (DVd) has a strong antiangiogenic activity in newly diagnosed multiple myeloma (MM) patients (PTS) [Abstract]. Blood. 2000; 96: 276b.
  • 39
    Anderson H, Scarffe JH, Lambert M, et al. VAD chemotherapy—toxicity and efficacy—in patients with multiple myeloma and other lymphoid malignancies. Hematol Oncol. 1987; 5: 213222.
  • 40
    Steinherz LJ, Steinherz PG, Tan C. Cardiac failure and dysrhythmias 6-19 years after anthracycline therapy: a series of 15 patients. Med Pediatr Oncol. 1995; 24: 352361.
  • 41
    Mancuso L, Marchi S, Canonico A. Dynamic left ventricular outflow obstruction and myocardial infarction following doxorubicin administration in a woman affected by unsuspected hypertrophic cardiomyopathy. Cancer Treat Rep. 1985; 69: 241244.
  • 42
    Koukourakis MI, Koukouraki S, Giatromanolaki A, et al. Liposomal doxorubicin and conventionally fractionated radiotherapy in the treatment of locally advanced non–small-cell lung cancer and head and neck cancer. J Clin Oncol. 1999; 17: 35123521.
  • 43
    Rajkumar SV, Fonseca R, Dispenzieri A, et al. Thalidomide in the treatment of relapsed multiple myeloma. Mayo Clin Proc. 2000; 75: 897901.
  • 44
    Juliusson G, Celsing F, Turesson I, Lenhoff S, Adriansson M, Malm C. Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma. Br J Haematol. 2000; 109: 8996.